Download
fimmu-12-630581.pdf 7,68MB
WeightNameValue
1000 Titel
  • In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries
1000 Autor/in
  1. Lei, Biao |
  2. Sleiman, M. Mahdi |
  3. Cheng, Qi |
  4. Tu, Zhenxiao |
  5. Zhu, Peng |
  6. Goddard, Martin |
  7. Martins, Paulo N. |
  8. Langerude, Logan |
  9. Nadig, Satish |
  10. Tomlinson, Stephen |
  11. Atkinson, Carl |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-07-29
1000 Erschienen in
1000 Quellenangabe
  • 12:630581
1000 Copyrightjahr
  • 2021
1000 Embargo
  • 2022-01-31
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.3389/fimmu.2021.630581 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358649/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Abstract/Summary
  • <jats:sec><jats:title>Introduction</jats:title><jats:p>Donor brain death (BD) is an unavoidable component of vascularized composite allograft (VCA) transplantation and a key contributor to ischemia-reperfusion injury (IRI). Complement is activated and deposited within solid organ grafts as a consequence of BD and has been shown to exacerbate IRI, although the role of BD and complement in VCA and the role it plays in IRI and VCA rejection has not been studied.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>BD was induced in Balb/c donors, and the VCA perfused prior to graft procurement with UW solution supplemented with or without CR2-Crry, a C3 convertase complement inhibitor that binds at sites of complement activation, such as that induced on the endothelium by induction of BD. Following perfusion, donor VCAs were cold stored for 6 hours before transplantation into C57BL/6 recipients. Donor VCAs from living donors (LD) were also procured and stored. Analyses included CR2-Crry graft binding, complement activation, toxicity, injury/inflammation, graft gene expression and survival.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Compared to LD VCAs, BD donor VCAs had exacerbated IRI and rejected earlier. Following pretransplant <jats:italic>in-situ</jats:italic> perfusion of the donor graft, CR2-Crry bound within the graft and was retained post-transplantation. CR2-Crry treatment significantly reduced complement deposition, inflammation and IRI as compared to vehicle-treated BD donors. Treatment of BD donor VCAs with CR2-Crry led to an injury profile not dissimilar to that seen in recipients of LD VCAs.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Pre-coating a VCA with CR2-Crry in a clinically relevant treatment paradigm provides localized, and therefore minimally immunosuppressive, protection from the complement-mediated effects of BD induced exacerbated IRI.</jats:p></jats:sec>
1000 Sacherschließung
lokal Mice, Inbred BALB C [MeSH]
lokal Mice, Inbred C57BL [MeSH]
lokal brain death
lokal Reperfusion Injury/prevention
lokal transplantation
lokal Immunosuppression Therapy [MeSH]
lokal Complement Inactivating Agents/therapeutic use [MeSH]
lokal Male [MeSH]
lokal Postoperative Complications/prevention
lokal immunogenicity
lokal preservation
lokal Recombinant Fusion Proteins/therapeutic use [MeSH]
lokal Immunology
lokal Vascularized Composite Allotransplantation [MeSH]
lokal Brain Death [MeSH]
lokal Humans [MeSH]
lokal Animals [MeSH]
lokal Reperfusion Injury/etiology [MeSH]
lokal ischemia reperfusion injury
lokal Molecular Targeted Therapy [MeSH]
lokal complement inhibition
lokal Mice [MeSH]
lokal Cells, Cultured [MeSH]
lokal vascularized composite allotransplantation
lokal graft treatment
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/TGVpLCBCaWFv|https://frl.publisso.de/adhoc/uri/U2xlaW1hbiwgTS4gTWFoZGk=|https://frl.publisso.de/adhoc/uri/Q2hlbmcsIFFp|https://frl.publisso.de/adhoc/uri/VHUsIFpoZW54aWFv|https://frl.publisso.de/adhoc/uri/Wmh1LCBQZW5n|https://frl.publisso.de/adhoc/uri/R29kZGFyZCwgTWFydGlu|https://frl.publisso.de/adhoc/uri/TWFydGlucywgUGF1bG8gTi4=|https://frl.publisso.de/adhoc/uri/TGFuZ2VydWRlLCBMb2dhbg==|https://frl.publisso.de/adhoc/uri/TmFkaWcsIFNhdGlzaA==|https://frl.publisso.de/adhoc/uri/VG9tbGluc29uLCBTdGVwaGVu|https://frl.publisso.de/adhoc/uri/QXRraW5zb24sIENhcmw=
1000 Hinweis
  • DeepGreen-ID: 2585fc9978b8415396a2eb72be38dbdb ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. U.S. Department of Defense |
  2. National Institutes of Health |
1000 Fördernummer
  1. -
  2. -
1000 Förderprogramm
  1. -
  2. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer U.S. Department of Defense |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer National Institutes of Health |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6474860.rdf
1000 Erstellt am 2024-04-11T13:01:38.411+0200
1000 Erstellt von 322
1000 beschreibt frl:6474860
1000 Zuletzt bearbeitet 2024-04-29T11:17:23.847+0200
1000 Objekt bearb. Mon Apr 29 11:17:23 CEST 2024
1000 Vgl. frl:6474860
1000 Oai Id
  1. oai:frl.publisso.de:frl:6474860 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source